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Abstract
Background & Aims: Although the prognosis of patients with occult hepatitis B virus (HBV) infection (OBI) is
usually benign, a small portion may undergo cirrhosis and subsequently hepatocellular carcinoma (HCC). We
studied the mechanism of life-long Integration of virus DNA into OBI host’s genome, of which may induce
hepatocyte transformation.
Methods: We applied HBV capture sequencing on single cells from an OBI patient who, developed multiple HCC
tumors and underwent liver resection in May 2013 at Tongji Hospital in China. Despite with the undetectable virus DNA
in serum, we determined the pattern of viral integration in tumor cells and adjacent non-tumor cells and obtained the
details of the viral arrangement in host genome, and furthermore the HBV integrated region in cancer genome.
Results: HBV captured sequencing of tissues and individual cells revealed that samples from multiple tumors shared two
viral integration sites that could affect three host genes, including CSMD2 on chr1 and MED30/EXT1 on chr8. Whole
genome sequencing further indicated one hybrid chromosome formed by HBV integrations between chr1 and chr8 that
was shared by multiple tumors. Additional 50 poorly differentiated liver tumors and the paired adjacent non-tumors
were evaluated and functional studies suggested up-regulated EXT1 expression promoted HCC growth. We further
observed that the most somatic mutations within the tumor cell genome were common among the multiple tumors,
suggesting that HBV associated, multifocal HCC is monoclonal in origin.
Conclusion: Through analyzing the HBV integration sites in multifocal HCC, our data suggested that the tumor cells
were monoclonal in origin and formed in the absence of active viral replication, whereas the affected host genes may
subsequently contribute to carcinogenesis.
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Background
Hepatitis B virus is a common cause of chronic liver infec-
tion throughout the world. Chronic HBV infection often
leads to the development of hepatocellular carcinoma
(HCC) [1]. The overall prognosis is poor as many patients
present with multifocal disease. Furthermore, radical liver
resection is typically ineffective as new tumors commonly
appear in the remnant liver. This highlights a longstanding
question in HCC carcinogenesis: when patients present
with multifocal liver disease, are the individual tumors of
a monoclonal or multiclonal origin [2, 3]? Many clinical
studies favor a monoclonal origin theory where multiple
small tumors in the liver are derived from a primary HCC
tumor through invading the inflow or outflow of the
hepatic vascular tree with subsequent intrahepatic spread
[4, 5]. Conversely a diffuse or multifocal theory of HCC
has been proposed, in which multiple HCC tumors are
derived independently from de novo mutations in a liver
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subject to a genetic field change caused by chronic viral
infection [6, 7].
Viral replication and viral DNA integration into host
chromosomes are two distinctive pathogenic mecha-
nisms of HBV-associated HCC [8–11]. In order to study
malignant transformation driven solely through viral in-
tegration, the tumor tissues should be obtained from pa-
tients who have entirely cleared HBV surface antigen
(HBsAg) or HBV e antigen (HBeAg). Occult hepatitis B
virus infection (OBI) is characterized by the persistence
of HBV-DNA in the liver tissue of individuals who suc-
cessfully clear the virus from the blood as suggested by
the loss of HBV antigens and the appearance of anti-HBV
antibodies [12]. While in the OBI state, the replication-
competent viruses are strongly suppressed in their activ-
ities by the host’s defense mechanisms. Therefore, the
prognosis of OBI is usually benign characterized by the
normal ALT levels and frequent loss of HBV-DNA in per-
ipheral, commonly showing the minimal risk of cirrhosis,
decompensation, and HCC, as well as the improved sur-
vival [12, 13]. Yet a small proportion of these patients do
develop HCC despite being free of actively replicating
virus [14].
Here, we studied one such OBI patient whom we believe
this scenario provides a valuable model to exclusively
examine effects of viral integration on liver carcinogenesis
and tumor progression.
Methods
Study subject
The study was approved by the Institutional Review
Board of Tongji Hospital, Tongji Medical College of
HUST, in Hubei province, China. More detailed descrip-
tion of the clinicopathologic features of the patient and
specimens can be found in the Additional file 1.
Single cell collection and amplification
The procedure can be found in the Additional file 1.
The HBV integration breakpoint detection procedure
We applied FuseSV (in-house software) to gather reads
mapped to individual HBV genome and detect HBV
integrations (Additional file 1: Figure S1).
Cell lines and cell culture
These were described in detail in the Additional file 1
and our previous study [15].
Results
Characterization of an OBI patient with multiple tumors
in liver with vascular metastatic invasion
The OBI patient in this study was a 47-year-old Chinese
male (Additional file 1: Table S1). Liver magnetic reson-
ance imaging (MRI) revealed a main lesion in the left
hepatic lobe, three smaller lesions in the right hepatic
lobe, tumor thrombi in right portal vein branch (PVTT)
and inferior vena cava (IVCTT/HVTT). These findings
indicated both intrahepatic and extrahepatic vascular
spread of HCC (Fig. 1).
Identifying all samples with the integrated HBV-B2 DNA
by virome capture sequencing (VCS)
We examined ten surgical specimens: T1 obtained from
the largest tumor site and three smaller liver tumors
found in the right hepatic lobe (T2-T4), biopsies from
the adjacent non-tumor liver tissue (N1-N4) as germline
controls, and embolic metastatic deposits of HCC in the
hepatic and portal veins (HVTT and PVTT). VCS data
identified the presence of the HBV_B2 subtype in all six
tumor samples with partial HBV genome covered (T1-
T4, HVTT and PVTT, mean depth = 79.16X, range:
47X-93X; mean coverage = 79.72%, range: 79–82%; Add-
itional file 1: Table S2, Additional file 1: Figure S2 and
Additional file 1: Figure S3). We identified HBV_B2
signals in all the four control samples (N1-N4, mean
depth = 16X, range: 9X-33X). Furthermore, 61 single nu-
cleotide variants (SNVs) within the HBV_B2 genome
were identified being shared by the six tumor samples
(Additional file 1: Table S3). We further noted all six
tumor samples were absent of the viral coding region for
the HBV X gene (Additional file 1: Figure S3), highlighting
an identical structure and alterations of HBV genome
shared by all lesions.
Seeking HBV integrations and viral rearrangements
To explore the underlying mechanism by which the
HBV X gene is truncated, we validated two HBV inte-
gration sites in host genome (chr1:34397064 and chr8:
118557326, Fig. 2a, Additional file 1: Table S2). One is
located in the intronic region of gene CSMD2 on chr1
and the other is located in the intergenic region of genes
MED30/EXT1 on chr8, respectively. These two integrations
repeatedly occurred in all six tumors, suggesting a mono-
clonal origin. We further discovered micro-homologous
bases from the junction sequences (Fig. 2a). In particular, at
the chr8 integration site, the adjacent two downstream
bases became micro-homologous due to the SNVs on
HBV_B2 genome (Fig. 2a, Additional file 1: Figure S3).
We found the two HBV integration sites resided on
different chromosomes. Only one viral breakpoint of
HBV integration met the 3-prime end (HBV_B2:1828) of
the truncated region on the constructed HBV genome
(Additional file 1: Figure S3). We found one inverse re-
arrangement on HBV genome whose one junction position
was just the 5-prime end (HBV_B2:1157) of the truncated
viral region (Fig. 2b, Additional file 1: Figure S3). In all six
tumors, the HBV genomic region, from the viral break-
point (HBV_B2:2136) in chr8 to the viral breakpoint
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(HBV_B2:2337) with the inverse rearrangement, displayed
a greater sequencing depth compared with other parts of
the viral genome (Fig. 2b, Additional file 1: Figure S3). This
suggested that the host integrations and the viral inversion
are phased together, resulting in a bridge between chr1 and
chr8 by HBV genome.
Single cell VCS data identifies heterogeneity within tumors
We next combined single cell sequencing with a virus-
capture approach to detect the presence of fragments of
viral DNA in individual cells. 264 cells were selected
from six tumors for DNA extraction and single cell VCS
analysis (Additional file 1: Table S2). We successfully
identified 229 cells with detectable HBV DNA (86.74%).
We detected the presence of the HBV_B2 genome in
219 out of 229 viral signal positive cells (95.63%, mean
depth = 117.61X, range, 1X-7443X, mean coverage =
67.62%, range, 27–79%) (Additional file 1: Table S4).
Consistent with the VCS data, we recalled 61 SNVs
within the HBV_B2 genome with a maximum coverage
of 79.38% in tumor tissues.
Within this HBV_B2 population, we identified 51.60%
(113/219) of tumor cells showing viral integrations on
chr1, 58.90% (129/219) on chr8, and 59.36% (130/219)
Fig. 1 Detection of multiple hepatocellular carcinomas (HCC) in the patient. Magnetic resonance imaging (MRI) reveals a 15 cm × 10 cm larger
lesion in the left hepatic lobe and multiple smaller lesions in the right hepatic lobe, all less than 3 cm in diameter (a). Yellow arrows indicate
multiple tumor foci of various sizes. MRI with contrast enhancement reveals tumor thrombosis involving the inferior vena cava (IVCTT), and the
right portal vein branch (PVTT), indicated by the red arrows, respectively in b, suggesting intrahepatic and extrahepatic vascular spread of HCC.
c shows representative photomicrographs of the multifocal invasive HCC that was profiled in this study. Of these foci, hematoxylin and eosin
staining is shown for the large tumor, T1, its adjacent cirrhosis tissue (Non-Tumor), the tumor invading portal vein (PVTT), and peripheral hepatic
vein (HVTT). Histologically, the HCC are of poor-to-moderate [16–18] differentiation with trabecular and solid patterns further evaluated by
immunohistochemical (IHC) staining with Arginase-1 (Arg-1; Upper panel in d) and Hepatocyte Paraffin-1 (HepPar-1; Lower panel in d)
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with the inversion of the HBV_B2 genome, respect-
ively. We identified HBV_B2 integrations that had un-
even distribution among cells from different tissues
suggesting tumor heterogeneity (Additional file 1:
Table S4). Despite this, it was possible to identify
“major events” that were shared by all tumor tissues
(Additional file 1: Table S5). We further identified 11
“minor events” characterized by genetic changes in at
least two cells (Additional file 1: Table S5). Among
them, 10 minor viral integrations were located within
five kilobases from the major events. All minor events
showed prevalent enrichment of the large-size micro-
homologies (Additional file 1: Table S5), a phenomenon
has been discovered in chimeric DNA rearrangements
during single cell Multiple Displacement Amplification
(MDA) [19, 20].
Revealing a common ‘local haplotype’ at HBV-integrated
loci within tumors by whole genome sequencing (WGS)
Next we performed WGS on all ten tissues. Consist-
ent with the VCS data, WGS data confirmed the
presence of HBV_B2 viral DNA in all six tumor sam-
ples and again identified HBV integrations at chr1
and chr8 (Additional file 1: Table S2).
For copy number variation (CNV) analysis, we next se-
lected sample N1 as the global control, which showed the
minimum depth of HBV_B2 genome (Additional file 1:
Table S2). In all tumor samples, we found that human gen-
omic segments flanked the HBV_B2 integrated sites (chr1:
34397064 and chr8:118557326) with a consistent increase
in copy number (CN, Additional file 1: Figure S5). In the
PVTT sample there were two copies of adjacent genomic
region upstream of the chr1-integrated position, three for
Fig. 2 Local haplotype of HBV-integrated genomic region in sample PVTT. a Human genomic region of chr1 and chr8 flanking HBV integrations
are divided into segments (A~D) by viral insertions. Breakpoints are noted by circled numbers. Sequencing depth spectrum (red for tumor, light-
blue for control) are displayed with copy numbers of segments. Dark-blue lines denote average depth of segments. For each segment junction,
micro-homologies in bilateral twenty base-pairs (pink for one-bp size; red for larger). Mutations on HBV genome were denoted by red asterisks.
Connection orientation of segments are noted by circled plus or minus symbol in red. b Constructed HBV_B2 genome is segmented (a~e) by
breakpoints with circled numbers. c Resolved alleles of local haplotype are indicated as coloured segments connected string with copy times.
The “circular junction” means HBV genome circular loop site. d Hybrid chromosome and copy number shift of chr1 and chr8 from normal cell to
tumor cell. Parental homologous chromosomes are in different colors
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the downstream genome segment, and three and four
copies for those regions on chr8, respectively. Moreover, six
tumor samples shared this CN pattern near the HBV_B2
integrations with a high Pearson correlation coefficient
(mean = 0.962, range: 0.875–0.997, Fig. 3a&b). Although
the slight CN difference could be caused by tumor cell pur-
ity (Additional file 1: Table S2), these six tumor samples
showed relatively similar CN distribution along the HBV_
B2 genome (Fig. 3c), suggesting a monoclonal origin.
To resolve the “local haplotype” of the HBV_B2 integra-
tion sites, we next analyzed the breakage of two integra-
tions on cancer genome and the fusion of chr 1 and 8
linked by a viral DNA bridge (Fig. 2). The shaped “bridge”
contained five viral segments, lacked “b” segment but had
a duplicated “d” HBV segment. Via this HBV “bridge”, the
tail (3-prime) of 8q was concatenated with chr 1p in the
reverse orientation, replacing the head (5-prime) of 1p.
This process generated one hybrid chromosome, whose
short arm consisted of a small region from 8q (the tail)
and a large region from 1p (Fig. 2c&d). Moreover, hetero-
zygosity analysis showed most of 1p and the whole of 1q
harbored minor frequency alleles. While the head (5-
prime) of 1p, the region replaced by tail of 8q and the
whole of chr8 indicated by loss of heterozygosity (LOH),
were potentially induced by HBV_B2 integrations and dis-
regulation of chromosome segregation during mitosis.
Note that one frequent LOH (chr1:53468857 to chr1:
67082731) existed on 1p among all tumor samples, (Add-
itional file 1: Figure S5). Together we hypothesize a model
that the integration of HBV_B2 results in formation of a
Fig. 3 Copy number comparison of HBV-integrated genomic region among six tumors. Segmentations of HBV-integrated human genomic region
and HBV genome in six tumor tissue samples were shown with copy number counts as Fig. 2. a chr1; b, chr8; c, HBV_B2 genome
Chen et al. Journal of Experimental & Clinical Cancer Research          (2019) 38:261 Page 5 of 11
hybrid chromosome between one homologous chromo-
some pair of chr1 and chr8. The remaining homologous
chr1 and chr8 lack of viral integration subsequently be-
came duplicated and triplicated to form two and three
copies within the tumor cell. Based on the CN count, the
large deletion on 1p should phase with the non-HBV-
integrated chr1 (Fig. 2d). This was compounded by mul-
tiple duplications of the region of 1q from the hybrid
chromosome in tumor cells (Fig. 2d), suggesting the po-
tential chromosome instability (CIN) at the centromere of
the hybrid chromosome, as there was a step change in CN
at 1q21.1 and 1q21.3 (Additional file 1: Figure S5).
Common genome-wide somatic alterations reveal a
monoclonal origin of multifocal HCC
To further understand the origin of tumor cells, we con-
ducted mutation analysis by calling genome-wide somatic
mutations from WGS data. We identified 35,165 somatic
SNVs and among them 495 SNVs located in genetic regions.
There were 12,110 SNVs (34.44%) shared by six tumor
tissues (unpublished data & Additional file 1: Figure S4A).
However, each individual tumor harboured abundant
unique SNVs, suggesting their heterogeneity of develop-
ment. T1 in comparison to other lesions had the largest
tumor size and correspondingly, contained the most unique
SNVs (4042). The T2-T4, PVTT and HVTT samples shared
4341 somatic SNVs, revealing their close relationship in evo-
lution. Moreover, the T4 and PVTT samples, which were
located close to each other, shared more unique SNVs than
any other pairwise tumor samples. Through hierarchical
clustering, the six tumor lesions were divided into three
clusters (T1, T4/PVTT, and T2/T3/HVTT; Additional file 1:
Figure S4B), of which were further confirmed by comparing
their genetic SNVs (Fig. 4a&b).
We detected that all six tumors gained global copy num-
ber that on average covered 91.41% of the genomic region
(Additional file 1: Figure S5A), generating a high-level
ploidy within tumor cells (mean = 7.73, Additional file 1:
Table S2). Furthermore, the copy number patterns were
consistent among all lesions (Additional file 1: Figure S5).
Overall arm level duplications were common along the
cancer genome, including among chromosomes 1q, 2, 4p,
5, 6, 7, 12, 15–22, X and Y, of which chr 1q had the highest
copy number. For each CNV region along the cancer gen-
ome, we calculated the mean and SD of the copy number
of the six tumor samples. Subsequently, a z-score could be
calculated for individual sample and its every given CNV
region, reflecting how much it has shifted from the average.
With the exception of T1, other five tumor samples had
low z-scores (− 1 to 1) of copy number variation through-
out the majority of their genomic region (mean ratio =
97.97%, Fig. 4c). In contrast, only 35.35% of the genomic
region of T1 demonstrated a low copy number variation,
with large z-scores (− 3 to − 1 or 1 to 3) measured at
chromosomes 3, 9, 10, 11, 14, 18, and 22, respectively (Fig.
4c). We next identified 3711 somatic structure variations
(SVs) and among them, 561 cases shared by all six lesions
(Fig. 4d & unpublished data). While comparing the number
of unique somatic SVs versus SNVs, we found individual
tumor samples contained higher proportion of unique som-
atic SVs (mean = 9.19%, range: 8.19–10.00%) than that of
somatic SNVs (mean = 3.76%, range: 1.40–11.49%). Among
all samples, T1 had the greatest number of unique somatic
SNVs but comparable number of unique somatic SVs.
HBV integration leads to altered expression of CSMD2
and EXT1
We further studied the two integration sites that were
common in all six tumors: the intronic region of CSMD2
on chr1 and the intergenic region of MED30-EXT1 on
chr8. The CSMD2 gene only retained a 3-prime remnant
of its genetic locus, and MED30 gene was entirely de-
leted with the lost part of chr8. In contrast, EXT1 gene
was retained with the integrated HBV_B2 segment lo-
cated upstream. Immunohistochemistry (IHC) analysis
of tumor biopsy samples confirmed a loss of CSMD2 and
enhanced EXT1 expression in tumor and PVTT cells
(Fig. 5a), whereasMED30 expression was unchanged (data
not shown). To evaluate the significance of this finding,
we conducted IHC staining on additional 50 poorly differ-
entiated liver tumors and the paired adjacent non-tumors.
The data revealed that the expression of CSMD2 and
EXT1 were significantly altered between non-tumors and
tumors in a large number of patients with HCC (Fig. 5b,
Wilcoxon signed rank test, P < 0.0001).
EXT1 promotes HCC cell growth in vitro and in vivo
To further explore the significance of elevated EXT1
expression in HCC, we analysed a panel of hepatic or
HCC cell lines for EXT1 expression by western blotting
(Additional file 1: Figure S6). We used retroviral transduc-
tion to overexpress EXT1 in low EXT1-expressing cell
lines, including HLF, Bel-7402, and MHCC-LM3. We then
knocked down EXT1 through transfecting lentiviruses car-
rying a doxycycline-inducible EXT1-targeting short hair-
pin RNA (shRNA) in high EXT1-expressing cell lines,
named Hep3B-shEXT1 and Huh7-shEXT1. Three shRNA
sequences were tested including shEXT1 1–5, 2–1, and
3–1 (Additional file 1). The success of the targeted overex-
pression or knockdown in HCC cell lines was confirmed
by western blotting (Fig. 6a). Cell Counting Kit-8 (CCK-8)
and colony formation assays revealed that overexpressing
EXT1 in HLF, Bel-7402, and MHCC-LM3 cells promoted
cell growth (Fig. 6b and Additional file 1: Figure S7). Fur-
thermore, in vitro tumorigenicity assays showed that
shRNA knockdown of EXT1 significantly decreased tumor
growth of Hep3B and Huh7 cells, compared with cells
treated with a scrambled shRNA control. We next used a
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xenograft animal model to assess the effect of altering
EXT1 expression on HCC cell line proliferation in vivo.
Consistent with in vitro studies, there was a significant re-
duction in tumor volume in mice that had received EXT1
deficient HCC cells compared with animals that received
control Hep3B and Huh7 cells (−vector). By contrast,
transplanted EXT1 overexpressing HCC cells resulted in
significantly larger tumors compared with animals that
received control HLF, Bel-7402, and MHCC-LM3 cells
(−vector) (Fig. 6c).
Discussion
We identify a patient with multifocal HCC without ac-
tive virus replication. He had successfully cleared viral
DNA from his blood and became immune to the virus,
yet years later subsequently developed HCC with the
evidence of HBV viral integration. Single cell sequencing
and virus DNA capture have the capacity to detect every
individual somatic event in parallel for comprehensively
identifying viral insertions and quantifying their frequen-
cies, providing us with the opportunity to interrogate
the global extent of viral impact on the human genome.
Previous studies based on parallel exome sequencing of
HBsAg-seropositive HCC, observed that the virus-affected
genes including VCAM1 and CDK14 only presented in
PVTT but not in the primary tumor, suggesting that genes
perturbed by viral integration may contribute to tumor in-
vasive capacity [9–11]. Here we compared the pattern of
HBV integrations and genome-wide somatic alterations
between primary and metastatic tumor cells through VCS
Fig. 4 Comparison of genome-wide somatic alterations among six tumors. a Venn diagram comparing the somatic SNVs in genetic region
among the six tumors. b Hierarchical clustering based on genetic somatic SNVs. c Distribution of copy number z-score along the genome of T1
and the other five tumor tissues. d Venn diagram comparing the somatic SVs among the six tumors
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and WGS. The multiple anatomically separate HCC le-
sions did not share same histological appearance, but
there was a strikingly similar pattern of HBV integrations
and somatic mutations. These included two HBV integra-
tions together with one inversion structure variation on
HBV genome induced the formation of hybrid chromo-
some between chr1 and chr8. Yet we found significant dif-
ferences between tumour cells. Profiles of genome-
wide somatic alterations allowed us to group the six
lesions into three clusters (T1, T2/T3/HVTT, and T4/
PVTT), reflecting their evolutionary relationship and
supporting that a monoclonal origin located at the
site of the largest tumor, T1.
Our functional studies confirmed that one of these
genes affected by two HBV_B2 integrations at chr1 and
chr8, CSMD2, showed a reduced expression in HCC sam-
ples compared with the adjacent non-tumor tissues by IHC
(Fig. 5). CSMD2 encoding a member of the C1r/C1s, Uegf,
Bmp1 (CUB) and sushi multiple domain protein (CSMD)
family – is a candidate TSG associated with colorectal can-
cer [21]. The altered expression of CSMD2 in HCC samples
may indicate a possible role in driving hepatocarcinogenesis.
Fig. 5 Detection of CSMD2 and EXT1 expression in liver by IHC. Upper and lower panels show the analysis of CSMD2 and EXT1 expression by IHC
staining in tumors, non-tumors, and PVTT from the same patient. CSMD2 is down-regulated and EXT1 is up-regulated in tumors and PVTT compared to
non-tumor tissues (a). Additional 50 poorly differentiated liver tumors and the paired adjacent non-tumor tissues were acquired to confirm the findings
(b). Wilcoxon signed rank test is used to determine the difference between tumors and non-tumors in CSMD2 expression (left panel) and EXT1
expression (right panel). CSDM2 scoring for adjacent non-tumor group as follows: n = 50, Median = 9, 25% Percentile = 6, 75% Percentile = 12, Mean =
8.1, SD = 3.5, SEM = 0.50; versus for tumor group as follows: n = 50, Median = 1, 25% Percentile = 0, 75% Percentile = 4, Mean = 2.7, SD = 3.4, SEM = 0.49.
EXT1 scoring for non-tumor group as follows: n = 50, Median = 2, 25% Percentile = 0, 75% Percentile = 4, Mean = 2.12, SD= 2.06, SEM= 0.29; versus for
tumor group as follows: n = 50, Median = 7, 25% Percentile = 4, 75% Percentile = 9.75, Mean = 6.86, SD= 3.86, SEM= 0.55
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However, CSMD2 is fairly large protein with approximately
380KDa molecular mass and therefore, at the time of our
manuscript preparation, we are unable to transduce its ex-
pression in HCC cell lines to further address its functions.
Conversely we found a viral integration that enhanced the
expression of the human exostosin 1 (EXT1) gene. Germline
mutations of EXTs have been linked with cause skeletal ab-
normalities, short stature and malignant transformation
from exostoses to chondrosarcomas [22]. In one report,
knockdown of EXT1 in multiple myeloma cells suppressed
tumor growth, resulting in a significantly extended survival
in animal model [23]. Although EXT1’s function in HCC is
not clear, it has been reported as one of three Interferon-
alpha (IFN-α)/5-fluorouracil (5-FU) therapy sensitizing
genes in HCC [24]. It is suggested that in the presence of
chemotherapy reagents, EXT1 as an endoplasmic reticulum
(ER)-resident protein may sensitize HCC cells to 5-FU
through ER stress, which is induced by alternating heparin
sulfate posttranslational modification. In the current study,
we for the first time show EXT1 levels are elevated in hu-
man HCC samples compared to the adjacent non-tumor.
Furthermore, overexpressing EXT1 in HCC induces the
tumor proliferation whereas knockdown EXT1 reduced
tumor growth in vitro and in vivo (Fig. 6). Although our
functional studies fail to observe that EXT1 plays roles in
tumor metastasis (Additional file 1: Figure S8), it may
suggest a carcinogenic role of EXT1 in continuing ex-
pansion of one of few malignantly altered hepatocytes
in the development of multiple HCC, whereas further
intra- or extra- hepatic spreading may require the dis-
tinctive mechanisms. Future studies will be ensured to
address the underlying mechanisms and also determine
whether EXT1 level in HCC tissues could serve as a
prognostic marker for cancer therapy.
Fig. 6 EXT1 promotes HCC cell growth in vitro and in vivo. a Western blot analysis shows HLF, Bel-7402, and MHCC-LM3 cells stably overexpressed with
EXT1, versus cells without transfection or transfected with control vector, respectively (upper panel). In lower panel, western blot analysis showed Huh-7
and Hep3-B cells stably knocked down with EXT1, versus cells without transfection or transfected with control vector, respectively. Three shRNA sequences
were tested including shEXT1 1–5, 2–1, and 3–1 (Additional file). GAPDH protein level was used as an internal control. b CCK-8 assay was performed for
the analysis of proliferation ability of the HCC cell lines stably overexpressed or knocked down with EXT1. Values represent the mean ± SEM of three
independent transfection experiments (p < 0.05). c The indicated cells were subjected to In vivo subcutaneous tumor growth curves. 2~4 × 106 tumor cells
were injected subcutaneously into the flank of nude mice (n = 6). Mice were sacrificed when tumor volume grew into around 1000mm3 and tumor
samples were collected, measured, and photographed. HCC cell lines stably overexpressed with EXT1 showed enhanced tumor growth, whereas
knockdown of EXT1 in vitro and in vivo both inhibited tumor growth
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Frequently, the direct roles of HBV in liver carcinogenesis
have been suggested. Among those, the HBV X gene shows
a transactivating effect linked to HCC via controlling cell
growth and apoptosis [25]. Previous studies mostly based
on studying HBsAg-positive HCC persons suggest that the
usage of this strategic viral breakpoint may facilitate HBV
insertions, leading to the formation of chimeric human fu-
sion genes, subsequently interfering with tumor suppres-
sors or imposing cis-regulatory effects on the expression of
downstream genes [9]. In contrast, the OBI patient in our
study with HBsAg-negative serology and undetectable viral
DNA in peripheral shows no integration of HBV X gene in
host genome. Similarly, Toyoda and colleagues studies the
HBV X gene integration in serologically HBV-negative pa-
tients. Though detecting the integration of HBV X gene se-
quence into liver genome in 9 of the 39 patients, they
conclude that there is no evidence that HBV-X integration
directly plays a role in HCC developments in these sero-
logically HBV-negative patients [26]. The discrepancy may
suggest that HBV X gene integration only occurs in some
of those serologically positive and viral replicating period in
association with a high risk for HCC. However, for those
OBI states, the replication-competent viruses are strongly
suppressed in their activities by the host’s defense mecha-
nisms, the alternative viral breakpoints may play dominant
roles in carcinogenesis.
Conclusions
In summary, this study provides deep insight into clonal
evolution of HCC in the absence of viral replication, sup-
porting a monoclonal HCC origin theory. The continuing
expansion of one of few malignantly altered hepatocytes
further promotes intra- or extra- hepatic spreading,
leading to the development of multiple HCC. It sug-
gests that viral integration and viral active replication
may serve as two separate mechanisms for the initi-
ation and subsequently maintenance of the trans-
formed stage in HCC.
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